ClinicalTrials.gg
CompletedNCT03402087Updated Feb 25, 2020

A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

A Phase 1 interventional study of Methotrexate and Leucovorin in Lupus and Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2018
with 1 other
Phase 1
3 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 2 that started in 2018, is one of 3 in phase 1, and was the 5th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to investigate effects of BMS-986165 on blood levels of methotrexate given as a single dose in healthy male patients.

03

Conditions studied

  • Lupus
  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • (BMI): 18.0 - 32.0 kg/m2
  • Normal renal function at screening

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, liver disease
  • Any indicated in the MTX package insert
  • History or presence of chronic bacterial or viral infection
  • History or presence of an disorder
  • Any significant acute or chronic medical illness
  • Active TB requiring treatment or documented latent TB within the previous 3 years
  • Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    BMS-986165+Methotrexate+Leucovorin

    Three treatments administered

    Drug: Methotrexate · Drug: Leucovorin · Drug: BMS-986165

Interventions

  • Specified dose on specified days

    Also known as: MTX

  • Specified dose on specified days

    Also known as: LEU

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 14 days

  2. Time to attain maximum observed plasma concentration (Tmax)

    Time frame: Approximately 14 days

  3. Area under the plasma concentration-time curve up to time T, where T is the last point with concentrations above the lower limit of quantitation [AUC(0-T)]

    Time frame: Approximately 14 days

  4. Area under the plasma concentration-time curve from time 0 to infinity [AUC(INF)]

    Time frame: Approximately 14 days

  5. Terminal elimination rate constant (kel)

    Time frame: Approximately 14 days

  6. Terminal elimination half life, calculated as 0.693/kel (T-HALF)

    Time frame: Approximately 14 days

  7. Apparent oral clearance (CL/F)

    Time frame: Approximately 14 days

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Approximately 19 days

  2. Incidence of serious adverse events (SAEs)

    Time frame: Approximately 19 days

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, 9728 NZ, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2018, 2 months.

Of 15 phase 1 interventional studies under Arthritis, Psoriatic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Jan 18, 2018
StartActual
Jan 8, 2018
Primary completionActual
Mar 20, 2018
CompletionActual
Mar 25, 2018
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03402087
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Jan 8, 2018
Primary completion
Mar 20, 2018
Completion
Mar 25, 2018
Last update
Feb 25, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion